U.S. Markets close in 5 hrs 7 mins

Independent Biostatisticians Recommend Vistagen Continue Late-Stage Anxiety Trial

·1 min read
  • Vistagen Therapeutics Inc (NASDAQ: VTGNcompleted an interim analysis of PALISADE-2, its second Phase 3 trial assessing drug candidate PH94B as an acute treatment of anxiety in adults with Social Anxiety Disorder.

  • The analysis concluded that PALISADE-2 should continue as planned.

  • Related: VistaGen Says Data From Late-Stage Anxiety Study 'Not Consistent' With Prior Positive Phase 2 Study.

  • Independent biostatisticians reviewed unblinded data from the 140 subjects who completed PALISADE-2 before the Company paused enrollment in the study in July 2022, following the announcement of topline results from its first Phase 3 trial, PALISADE-1.

  • The independent biostatisticians recommended that Vistagen continue PALISADE-2 as planned to the full enrollment of 208 subjects without adjusting the study size.

  • Vistagen expects topline results from PALISADE-2 in the first half of 2023.

  • Price Action: VTGN shares are up 21.8% at $0.20 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.